AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36062550 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (testing and in-person feedback with care-coordinator calls)
Number of subjects: 119
Study 36062550 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (no intervention)
Number of subjects: 119
Study 34154759 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily
Number of subjects: 100
Study 34154759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32938746 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitors
Number of subjects: 216558
Study 32938746 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 216558
Study 32938746 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 216558
Study 615916032 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PVI
Number of subjects: 120
Study 615916032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVI
Number of subjects: 120
Study 615916032 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (preoperative)
Number of subjects: 120
Study 34524700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban for thromboprophylaxis
Number of subjects: 76
Study 34524700 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 76
Study 32776980 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal communication about contraception
Number of subjects: 1020
Study 32776980 — intervention group
Group type: EXPERIMENTAL
Intervention: Wives' reports of spousal communication
Number of subjects: 1020
Study 32776980 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands' reports of spousal communication
Number of subjects: 1020
Study 35590307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamboo salt herbal toothpaste
Number of subjects: 60
Study 35590307 — intervention group
Group type: COMPARATOR
Intervention: Conventional non‐herbal toothpaste
Number of subjects: 60
Study 33361414 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning package
Number of subjects: 97
Study 33361414 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based teaching
Number of subjects: 97
Study 32456679 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for HPV testing
Number of subjects: 868
Study 36043784 — intervention group
Group type: EXPERIMENTAL
Intervention: OEP (OEPG; n=12)
Number of subjects: 36
Study 36043784 — intervention group
Group type: EXPERIMENTAL
Intervention: OEP plus DT (OEPDTG; n=12)
Number of subjects: 36
Study 36043784 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n=12)
Number of subjects: 36
Study 32768283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk factors (CMRF) prevalence
Number of subjects: 3414
Study 34352501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer perceptron classifier (MLPC) modeling
Number of subjects: 0
Study 34352501 — intervention group
Group type: COMPARATOR
Intervention: Support vector machine (SVM)
Number of subjects: 0
Study 33651896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (1.5 mg.kg-1 bolus, 2 mg.kg-1.h-1 infusion intra-operatively, 1.33 mg.kg-1.h-1 subcutaneous infusion postoperatively for up to 12 hours)
Number of subjects: 150
Study 33651896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 150
Study 33127948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed exercise program (balance exercise plus resistance exercise)
Number of subjects: 60
Study 33127948 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 60
Study 33127948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed exercise program
Number of subjects: 60
Study 34747977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nadolol
Number of subjects: 71
Study 34747977 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol
Number of subjects: 71
Study 33063610 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H3 receptor gene variants (specifically rs3787430 and rs74627870)
Number of subjects: 248
Study 33063610 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H3 receptor gene variant (rs13042865)
Number of subjects: 248
Study 33188301 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low Carbohydrate (HLC) diet
Number of subjects: 609
Study 33188301 — intervention group
Group type: COMPARATOR
Intervention: Healthy Low Fat (HLF) diet
Number of subjects: 609
Study 33188301 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low Carbohydrate (HLC) diet (men)
Number of subjects: 609
Study 33188301 — intervention group
Group type: COMPARATOR
Intervention: Healthy Low Fat (HLF) diet (women)
Number of subjects: 609
Study 35017254 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCO-TreC electronic diary
Number of subjects: 136
Study 35017254 — intervention group
Group type: COMPARATOR
Intervention: Standard paper diary
Number of subjects: 136
Study 33863665 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS treatment in patients with PAPP ≤ 0.583
Number of subjects: 550
Study 33863665 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS treatment in patients with HFrEF and PAPP ≤ 0.583
Number of subjects: 550
Study 33863665 — intervention group
Group type: COMPARATOR
Intervention: CardioMEMS treatment in patients with PAPP > 0.583 or HF with preserved EF (HFpEF)
Number of subjects: 550
Study 35341615 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-Based Case Management (SBCM)
Number of subjects: 300
Study 35341615 — intervention group
Group type: COMPARATOR
Intervention: Screening, Assessment, and Referral (SAR)
Number of subjects: 300
Study 34751657 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO (electronic PRO)
Number of subjects: 678
Study 34751657 — intervention group
Group type: COMPARATOR
Intervention: P&P (paper-and-pencil)
Number of subjects: 678
Study 34751657 — intervention group
Group type: COMPARATOR
Intervention: P&P
Number of subjects: 678
Study 34751657 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO
Number of subjects: 678
Study 35443727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse navigation program
Number of subjects: 0
Study 35443727 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 0
Study 34248041 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dose of terlipressin (response-guided titration method)
Number of subjects: 161
Study 34248041 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of terlipressin
Number of subjects: 161
Study 34248041 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dose of terlipressin
Number of subjects: 161
Study 32825846 — intervention group
Group type: EXPERIMENTAL
Intervention: Various healthcare interventions in RCTs
Number of subjects: 300
Study 32825846 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely available Bayesian prediction model
Number of subjects: 300
Study 32825846 — intervention group
Group type: EXPERIMENTAL
Intervention: User-friendly tool for trial investigators
Number of subjects: 300
Study 34117147 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT
Number of subjects: 539
Study 34117147 — intervention group
Group type: COMPARATOR
Intervention: CWT
Number of subjects: 539
Study 34976609 — intervention group
Group type: EXPERIMENTAL
Intervention: Online skin self-examination (SSE) education
Number of subjects: 1000
Study 34976609 — intervention group
Group type: COMPARATOR
Intervention: Active control arm
Number of subjects: 1000
Study 36420366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation (SM)
Number of subjects: 50
Study 36420366 — intervention group
Group type: COMPARATOR
Intervention: Muscle energy technique (MET)
Number of subjects: 50
Study 33203449 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital crowdsourced intervention including 24 images and four short videos about HIV testing and safe sexual behaviors, and HIV self-test services provided by the study team.
Number of subjects: 500
Study 33203449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 500
Study 36214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Demisexual individuals
Number of subjects: 119181
Study 36214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pansexual individuals
Number of subjects: 119181
Study 36214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender nonconforming FAB individuals
Number of subjects: 119181
Study 36214479 — intervention group
Group type: COMPARATOR
Intervention: All other sexual and gender identity groups
Number of subjects: 119181
Study 33956075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 monthly injections)
Number of subjects: 205
Study 33956075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with panretinal photocoagulation (PRP)
Number of subjects: 205
Study 33956075 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 205
Study 33956075 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with PRP
Number of subjects: 205
Study 32893274 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 90
Study 32893274 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 32893274 — intervention group
Group type: COMPARATOR
Intervention: C-MAC video-laryngoscope
Number of subjects: 90
Study 34137277 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft
Number of subjects: 20
Study 34137277 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived demineralized bone matrix (DMBM)
Number of subjects: 20
Study 34920553 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical telerehabilitation
Number of subjects: 0
Study 34920553 — intervention group
Group type: COMPARATOR
Intervention: Periodic newsletters (Control)
Number of subjects: 0
Study 35867859 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroidal mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 0
Study 35867859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34616489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus best supportive care (BSC)
Number of subjects: 413
Study 34616489 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 413
Study 32493715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AMY1 genetic risk score (GRS) with high dietary carbohydrate intake
Number of subjects: 32054
Study 32493715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AMY1 genetic risk score (GRS) with low dietary carbohydrate intake
Number of subjects: 32054
Study 32493715 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized dietary intervention over 2 years
Number of subjects: 32054
Study 35771645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified training
Number of subjects: 23
Study 35771645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 35771645 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper period after intensified training
Number of subjects: 23
Study 34497078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive use of an internet-based self-management intervention (priovi)
Number of subjects: 204
Study 34497078 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) by treating psychiatrist and/or psychotherapist
Number of subjects: 204
Study 34497078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 204
Study 32012453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 813
Study 32012453 — intervention group
Group type: COMPARATOR
Intervention: >1-month DAPT
Number of subjects: 813
Study 35267951 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL) treatment for 4 months
Number of subjects: 82
Study 33619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariable-adjusted summary associations in two-sample Mendelian randomization (MR)
Number of subjects: 0
Study 33619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of waist circumference for body mass index
Number of subjects: 0
Study 32780921 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week alarm management training course based on the theory of planned behaviour
Number of subjects: 93
Study 32780921 — intervention group
Group type: COMPARATOR
Intervention: Regular training (Control)
Number of subjects: 93
Study 35146039 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 1515
Study 35146039 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 1515
Study 35146039 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Number of subjects: 1515
Study 35146039 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 and PCV13
Number of subjects: 1515
Study 34873046 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy-based counterspeech
Number of subjects: 1350
Study 34873046 — intervention group
Group type: COMPARATOR
Intervention: Humor-based counterspeech
Number of subjects: 1350
Study 34873046 — intervention group
Group type: COMPARATOR
Intervention: Warning of consequences-based counterspeech
Number of subjects: 1350
Study 37021410 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ezetimibe (EZE) tablets (test product)
Number of subjects: 24
Study 37021410 — intervention group
Group type: COMPARATOR
Intervention: 10 mg ezetimibe (EZE) tablets (reference product)
Number of subjects: 24
Study 37021410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference products
Number of subjects: 24
Study 33212159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 92
Study 33212159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 32890814 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Creating Futures (SSCF) intervention
Number of subjects: 15
Study 35695720 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6-15 mg/d)
Number of subjects: 86
Study 35695720 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-30 mg/d)
Number of subjects: 86
Study 34023351 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 12 or 16 weeks
Number of subjects: 177
Study 34023351 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) with ribavirin for 12 weeks
Number of subjects: 177
Study 34023351 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 16 weeks
Number of subjects: 177
Study 34023351 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent NS3 RASs
Number of subjects: 177
Study 34023351 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent NS5A RASs
Number of subjects: 177
Study 32575945 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted artery perfusion of verapamil and chemotherapy drugs
Number of subjects: 60
Study 32575945 — intervention group
Group type: COMPARATOR
Intervention: Targeted artery perfusion of chemotherapy drugs alone (Control)
Number of subjects: 60
Study 35692038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100 unit/kg/day)
Number of subjects: 94
Study 35692038 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg/day)
Number of subjects: 94
Study 35692038 — intervention group
Group type: COMPARATOR
Intervention: Control (hypertonic saline only)
Number of subjects: 94
Study 33707050 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Exposure Index (EIT)
Number of subjects: 10
Study 33707050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviation Index (DI)
Number of subjects: 10
Study 33707050 — intervention group
Group type: COMPARATOR
Intervention: Default values for EIT
Number of subjects: 10
Study 33707050 — intervention group
Group type: COMPARATOR
Intervention: Acceptable EI range
Number of subjects: 10
Study 35643717 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34930979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten (4 tablets/day)
Number of subjects: 390
Study 34930979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten (8 tablets/day)
Number of subjects: 390
Study 34930979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 35947279 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-guided pelvic floor exercise therapy (BFT)
Number of subjects: 65
Study 35947279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 65
Study 35947279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BFT and dapoxetine 30 mg
Number of subjects: 65
Study 35947279 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 65
Study 33536096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish consumption (about 300 g/week for 12 weeks)
Number of subjects: 199
Study 36167363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose high-intensity training (1×4 min intervals at ~90% of maximal heart rate and 2×4 repetitions strength training at ~90% of 1 repetition maximum)
Number of subjects: 40
Study 36167363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose high-intensity training (4×4 min intervals at ~90% of maximal heart rate and 4×4 repetitions strength training at ~90% of 1 repetition maximum)
Number of subjects: 40
Study 33683035 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar (B) + Poultry Manure (PM) + Urea
Number of subjects: 15
Study 33683035 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry Manure (PM)
Number of subjects: 15
Study 33683035 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 33683035 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar (B)
Number of subjects: 15
Study 32638463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of botulinum toxin type A once a month for 4 months
Number of subjects: 20
Study 32638463 — intervention group
Group type: COMPARATOR
Intervention: Four sessions of CO2 laser therapy at 1 month interval followed by topical application of botulinum toxin A
Number of subjects: 20
Study 36079824 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt intake (175 g of plain organic milk yoghurt daily for 8 weeks)
Number of subjects: 52
Study 36079824 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet (Control group)
Number of subjects: 52
Study 33661692 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective-change intervention
Number of subjects: 155
Study 33661692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perspective-change intervention)
Number of subjects: 155
Study 35798751 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nail drops
Number of subjects: 105
Study 35798751 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care
Number of subjects: 105
Study 35798751 — intervention group
Group type: COMPARATOR
Intervention: Nail polish
Number of subjects: 105
Study 33782047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 32069218 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet with added exercise (PDEX)
Number of subjects: 28
Study 32069218 — intervention group
Group type: COMPARATOR
Intervention: Paleolithic diet (PD)
Number of subjects: 28
Study 34763338 — intervention group
Group type: COMPARATOR
Intervention: 3% Hypertonic Saline (HS), 5 mL/kg as continuous infusion, titrated every 6 hours to achieve serum sodium of <160 (Group A; n = 26)
Number of subjects: 51
Study 34763338 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Mannitol (MT), 1 g/kg as IV bolus, repeated every 6 hours (Group B; n = 25)
Number of subjects: 51
Study 34404237 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol and clopidogrel
Number of subjects: 1879
Study 34404237 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-monotherapy
Number of subjects: 1879
Study 34404237 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT using cilostazol and aspirin
Number of subjects: 1879
Study 34404237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-monotherapy
Number of subjects: 1879
Study 33119477 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group: radiation with capecitabine combined with weekly irinotecan (80 mg/m2 for UGT1A1*1*1 or 65 mg/m2 for UGT1A1*1*28)
Number of subjects: 356
Study 33119477 — intervention group
Group type: COMPARATOR
Intervention: Control group: pelvic radiation of 50 Gy/25 fractions with concurrent capecitabine, followed by oxaliplatin and capecitabine
Number of subjects: 356
Study 33119477 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 356
Study 33119477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 356
Study 33119477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 356
Study 35876837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 30 minutes in the morning at 10,000 lux for 6 weeks
Number of subjects: 22
Study 35876837 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL) for 30 minutes in the morning at 19 lux for 6 weeks
Number of subjects: 22
Study 33574141 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted spatial navigation intervention (5 hours/week for 16 weeks, total: 80 hours)
Number of subjects: 84
Study 33574141 — intervention group
Group type: COMPARATOR
Intervention: Active control group (watching educational videos and answering subjective questions)
Number of subjects: 84
Study 35238694 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback during active reaching task
Number of subjects: 20
Study 35238694 — intervention group
Group type: COMPARATOR
Intervention: No auditory feedback during active reaching task
Number of subjects: 20
Study 34288404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (DEX) dietary challenge
Number of subjects: 20
Study 34288404 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) dietary challenge
Number of subjects: 20
Study 35802667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 232